SCHEMBL25136336

SCHEMBL25136336

CC(C)(C)OC(=O)N[C@H]1C[C@H](Oc2ccccc2)C1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.56
MAOB P27338 1/20 0.56
KMT2A Q03164 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
EPHX2 P34913 2/20 0.50
BTK Q06187 3/20 0.47
KCNA3 P22001 1/20 0.44
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
DRD2 P14416 2/20 0.42
USP30 Q70CQ3 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
PIK3CD O00329 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30182719 1.00 KDM1A (0.56) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL30212203 0.90 KDM1A (0.50) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL25741446 0.88 BTK (0.58) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL29126597 0.88 EPHX2 (0.48) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL24078617 0.88 EPHX2 (0.48) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL2647959 0.87 KDM1A (0.62) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL23951807 0.87 KDM1A (0.48) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL14647010 0.87 KDM1A (0.62) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL23951710 0.86 KDM1A (0.47) KDM1AMAOBKMT2AL3MBTL1EPHX2
SCHEMBL21996735 0.86 KDM1A (0.45) KDM1AMAOBKMT2AL3MBTL1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. 2023-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CD38, CXCR4, FCGRT KDM1A 1511/4885MAOB 1380/4885KMT2A 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.